Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding trial of Yi'nao Jieyu Granules for major depressive disorder
ChiCTR2100053508Phase 2Recruiting
- Sponsor
- Beijing Anding Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Yi'nao Jieyu Granules in major depressive disorder (MDD) (4 arms), sponsored by Beijing Anding Hospital. Primary endpoints: Montgomery-Eisenberg Depression Scale at week 8, Hamilton Depression Rating Scale at week 8 and 7 more. Started Mar 2021; status: recruiting.
02
Drugs
Yi'nao Jieyu Granules
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2100053508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053508.